Lirentelimab

莱瑞利单抗

Report date: 2026/02/10 20:00:22

Base Information

Drug NameLirentelimab
Drug Alias NameAntolimabAK-002AK 002
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionMast cells inhibitorsSialic acid-binding Ig-like lectin 8 inhibitors
TargetsSialic acid-binding Ig-like lectin 8
Therapy Area/IndicationsEosinophilic gastroenteritis (EG)Chronic UrticariaDermatitis, Atopic +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandNetherlands +[5] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesJohns Hopkins University School Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAllakos Inc
Active IndicationsN/A
Inactive IndicationsEosinophilic gastroenteritis (EG)Chronic UrticariaDermatitis, Atopic +[8] 

Other Information

ATC CodeN/A
Related LinksN/A